載入中
NASDAQHealthcareMedical - Diagnostics & Research
最新資料
US$12.64
−US$0.58 · -4.39%
Freenome is an early cancer detection company developing blood-based screening tests to identify cancer in its earliest, most treatable stages. The company's proprietary multiomics discovery platform analyzes circulating cell-free DNA methylation patterns at single-base resolution alongside additional biomarkers to detect multiple cancers. Freenome's first commercial-stage test, SimpleScreen CRC for colorectal cancer, is under review by the U.S. Food and Drug Administration (FDA).
收盤時
US$12.64
−US$0.58 · -4.39%
盤後
US$12.70
+US$0.06 · +0.47%
10月13日 下午7:47 ET
盤中時間採用ET。市場資料可能有所延遲。
Freenome is an early cancer detection company developing blood-based screening tests to identify cancer in its earliest, most treatable stages. The company's proprietary multiomics discovery platform analyzes circulating cell-free DNA methylation patterns at single-base resolution alongside additional biomarkers to detect multiple cancers. Freenome's first commercial-stage test, SimpleScreen CRC for colorectal cancer, is under review by the U.S. Food and Drug Administration (FDA).
日內區間
目前US$12.64
52週區間
目前US$12.64
盤中時間採用ET。市場資料可能有所延遲。
Freenome is an early cancer detection company developing blood-based screening tests to identify cancer in its earliest, most treatable stages. The company's proprietary multiomics discovery platform analyzes circulating cell-free DNA methylation patterns at single-base resolution alongside additional biomarkers to detect multiple cancers. Freenome's first commercial-stage test, SimpleScreen CRC for colorectal cancer, is under review by the U.S. Food and Drug Administration (FDA).
日內區間
目前US$12.64
52週區間
目前US$12.64
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$18.25
上漲空間 44.38%報告持有此股票曝險的交易所交易基金。
ARK Genomic Revolution ETFARKG1431.78萬0.70%22.19億 USD0.75%US$48.51-1.96%
Schwab U.S. Small-Cap ETFSCHA371萬0.02%217.13億 USD0.03%US$32.56-0.31%
iShares Core S&P Total U.S. Stock Market ETFITOT109.28萬0.00%979.68億 USD0.03%US$169.34-0.05%
Fidelity Nasdaq Composite Index ETFONEQ50.67萬—109.4億 USD0.21%US$107.2-0.15%
Schwab U.S. Broad Market ETFSCHB43.27萬0.00%453.22億 USD0.03%US$29.85-0.08%
T. Rowe Price Exchange-Traded Funds, Inc. - T. Rowe Price Health Care ETFTMED20.47萬0.62%3277.95萬 USD0.44%US$33.0069-1.87%
T. Rowe Price Innovation Leaders ETFTNXT2.97萬0.15%1953.45萬 USD0.49%US$28.8644-0.47%
T. Rowe Price Small Cap ETFTSEE1.48萬0.14%1042.53萬 USD0.59%US$24.445-0.91%ARK Genomic Revolution ETFARKGSchwab U.S. Small-Cap ETFSCHAiShares Core S&P Total U.S. Stock Market ETFITOTFidelity Nasdaq Composite Index ETFONEQSchwab U.S. Broad Market ETFSCHBT. Rowe Price Exchange-Traded Funds, Inc. - T. Rowe Price Health Care ETFTMEDT. Rowe Price Innovation Leaders ETFTNXTT. Rowe Price Small Cap ETFTSEEAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
